Last update Aug. 6, 2022

Pancuronium Bromide

Likely Compatibility

Fairly safe. Mild or unlikely adverse effects. Compatible under certain circumstances. Follow-up recommended. Read Commentary.

It is a non-depolarizing muscle relaxant drug with a peripheral action that is used as premedication for endotracheal intubation, general anesthesia and mechanical ventilation. Intravenous administration.

At latest update, no relevant published data concerning excretion into breast milk were found.

Because a relatively high molecular-weight and a high protein-binding capacity, excretion into breast milk is thought to be low.

Also, quaternary ammonium muscle relaxants are poorly absorbed from the gastro-intestinal tract; its low oral bioavailability renders the pass of this agent to the infant's plasma highly unlikely. (Dalal 2014, Spigset 1994)

Pancuronium does not prevent a mother from breast feeding her baby shortly after recovering from anesthesia if she is awake and in good condition.

Experts authors consider the use of this medication to be probably compatible during breastfeeding. (Briggs 2015)

However, other muscle relaxants with a more rapid elimination time period and better known drugs are preferred.

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.
DONATE NOW

Other names

Pancuronium Bromide in other languages or writings:

Group

Pancuronium Bromide belongs to this group or family:

Tradenames

Main tradenames from several countries containing Pancuronium Bromide in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. ≈ 0 %
Molecular weight 733 daltons
Protein Binding 85 %
VD 0.1 - 0.2 l/Kg
T½ 1.5 - 3 hours

References

  1. Briggs GG, Freeman RK, Towers CV, Forinash AB. Drugs in Pregnancy and Lactation: A Reference Guide to Fetal and Neonatal Risk. Wolters Kluwer Health. Tenth edition (acces on line) 2015
  2. Dalal PG, Bosak J, Berlin C. Safety of the breast-feeding infant after maternal anesthesia. Paediatr Anaesth. 2014 Abstract
  3. Ferriols Lisart R,Ferriols Lisart F. Farmacología clínica y usos terapéuticos del Mivacurio. Farm Hosp. 1997 Full text (in our servers)
  4. Spigset O. Anaesthetic agents and excretion in breast milk. Acta Anaesthesiol Scand. 1994 Abstract
  5. Dailey PA, Fisher DM, Shnider SM, Baysinger CL, Shinohara Y, Miller RD, Abboud TK, Kim KC. Pharmacokinetics, placental transfer, and neonatal effects of vecuronium and pancuronium administered during cesarean section. Anesthesiology. 1984 Abstract
  6. Somogyi AA, Shanks CA, Triggs EJ. Clinical pharmacokinetics of pancuronium bromide. Eur J Clin Pharmacol. 1976 Abstract

Total visits

5,746

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM